



DEPARTMENT OF THE AIR FORCE  
59TH MEDICAL WING (AETC)  
JOINT BASE SAN ANTONIO - LACKLAND TEXAS

3 JAN 2017

MEMORANDUM FOR SGCEE

ATTN: CAPT JOHN BENNION

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

1. Your paper, entitled **Dose Uniformity of Topical Corticosteroid Ophthalmic Medications: Flourometholone Acetate 0.1% Suspension and Loteprednol Etabonate 0.5% Lotemax** presented at/published to **Journal of Ocular Pharmacology and Therapeutics** in accordance with MDWI 41-108, has been approved and assigned local file #**17014**.
2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.
3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are 59 MDW staff member, we can forward your request for funds to the designated wing POC.
4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

*Linda Steel-Goodwin*

LINDA STEEL-GOODWIN, Col, USAF, BSC  
Director, Clinical Investigations & Research Support

## PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

### INSTRUCTIONS

USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING

1. The author must complete page two of this form:
  - a. In Section 2, add the funding source for your study [ e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SG5 O&M); SG5 R&D; Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed Medical Research Program (CDMRP) ; Grants; etc.]
  - b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.
2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.
3. Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.
4. Attach a copy of your abstract, paper, poster and other supporting documentation.
5. Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.
6. On page 2, have either your unit commander, program director or immediate supervisor:
  - a. Print their name, rank/grade, title; sign and date the form in the approving authority's signature block or use an electronic signature.
7. Submit your completed form and all supporting documentation to the CRD for processing (59crdpubspres@us.af.mil). If you have any questions or concerns, please contact the 59 CRD/ Publications and Presentations Section at 292-7141 for assistance.
8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDW/PA) for review and then forward you a final letter of approval or disapproval.
9. Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. **Note:** For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.
10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DITC). See 59 MDWI 41-108, *Presentation and Publication of Medical and Technical Papers*, for additional information.

**NOTE:** All abstracts, papers, posters, etc., should contain the following disclaimer statement:

***"The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"***

**NOTE:** All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:


***"The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02\_AFI 40-402."***

**NOTE:** All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401\_IP :

***"The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."***



<b>PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS</b>			
1. TO: CLINICAL RESEARCH	2. FROM: (Author's Name, Rank, Grade, Office Symbol) John Bennion, Capt, 59th SGC/SGCEE	3. GME/GHSE STUDENT: <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO	4. PROTOCOL NUMBER: 397493-3
5. PROTOCOL TITLE: ( <b>NOTE:</b> For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.) Dose uniformity of topical corticosteroid ophthalmic medications: flourometholone acetate 0.1% suspension and loteprednol etabonate 0.5% <span style="float: right;">+6</span>			
6. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED: Dose uniformity of topical corticosteroid ophthalmic medications: flourometholone acetate 0.1% suspension and loteprednol etabonate 0.5% <span style="float: right;">+6</span>			
7. FUNDING RECEIVED FOR THIS STUDY? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO FUNDING SOURCE:			
8. DO YOU NEED FUNDING SUPPORT FOR PUBLICATION PURPOSES: <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO			
9. IS THIS MATERIAL CLASSIFIED? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO			
10. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO <b>NOTE:</b> If the answer is YES then attach a copy of the Agreement to the Publications/Presentations Request Form.			
11. MATERIAL IS FOR: <input checked="" type="checkbox"/> DOMESTIC RELEASE <input type="checkbox"/> FOREIGN RELEASE CHECK APPROPRIATE BOX OR BOXES FOR APPROVAL WITH THIS REQUEST. ATTACH COPY OF MATERIAL TO BE PUBLISHED/PRESENTED.			
<input checked="" type="checkbox"/> 11a. PUBLICATION/JOURNAL (List intended publication/journal.) Journal of Ocular Pharmacology and Therapeutics			
<input type="checkbox"/> 11b. PUBLISHED ABSTRACT (List intended journal.)			
<input type="checkbox"/> 11c. POSTER (To be demonstrated at meeting: name of meeting, city, state, and date of meeting.)			
<input type="checkbox"/> 11d. PLATFORM PRESENTATION (At civilian institutions: name of meeting, state, and date of meeting.)			
<input type="checkbox"/> 11e. OTHER (Describe: name of meeting, city, state, and date of meeting.)			
12. EXPECTED DATE WHEN YOU WILL NEED THE CRD TO SUBMIT YOUR CLEARED PRESENTATION/PUBLICATION TO DTIC <b>NOTE:</b> All publications/presentations are required to be placed in the Defense Technical Information Center (DTIC).			
DATE December 06, 2016			
13. 59 MDW PRIMARY POINT OF CONTACT (Last Name, First Name, M.I., email) Bennion, John L; john.l.bennion.mil@mail.mil			14. DUTY PHONE/PAGER NUMBER 210-594-6174
15. AUTHORSHIP AND CO-AUTHOR(S) List in the order they will appear in the manuscript.			
LAST NAME, FIRST NAME AND M.I.	GRADE/RANK	SQUADRON/GROUP/OFFICE SYMBOL	INSTITUTION (If not 59 MDW)
a. Primary/Corresponding Author Bennion, John L	Capt	59th TRS SGC/SGCEE	
b. Stevens, Charlton E	Capt	959th CSPS/MCHE-ZDM-M	959 CSPS
c. Caldwell, Matthew C	Lt Col	59th MDW SGC/SGCEE	
d. Townley, James R	Maj	59th MDW SGC/SGCEE	
e. Apsey, Douglas A	Civ	59th MDW SGC/SGCEP	
f. Schwertner, Harvey A	Civ	59th MDW CSPG/SGVU	
I CERTIFY ANY HUMAN OR ANIMAL RESEARCH RELATED STUDIES WERE APPROVED AND PERFORMED IN STRICT ACCORDANCE WITH 32 CFR 219, AFMAN 40-401 JP, AND 59 MDWI 41-108. I HAVE READ THE FINAL VERSION OF THE ATTACHED MATERIAL AND CERTIFY THAT IT IS AN ACCURATE MANUSCRIPT FOR PUBLICATION AND/OR PRESENTATION.			
16. AUTHOR'S PRINTED NAME, RANK, GRADE John Bennion, CAPT, 0-3		17. AUTHOR'S SIGNATURE BENNION JOHN L.1386423454 <small>Digitally signed by BENNION JOHN L.1386423454 DN: cn=JOHN L.1386423454, o=59TH SGC, ou=USAF email=BENNION JOHN L.1386423454 Date: 2016.12.06 15:06:41 -0500</small>	18. DATE December 06, 2016
19. APPROVING AUTHORITY'S PRINTED NAME, RANK, TITLE James Richard Townley, MAJ Cornea and Refractive Surgeon		20. APPROVING AUTHORITY'S SIGNATURE TOWNLEY JAMES RICHARD.III.10 13936532 <small>Digitally signed by TOWNLEY JAMES RICHARD.III.10 DN: cn=JAMES RICHARD.III.10, o=59TH SGC, ou=USAF email=TOWNLEY JAMES RICHARD.III.10 Date: 2016.12.13 15:51:31 -0500</small>	21. DATE December 13, 2016

<b>PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS</b>			
<b>1st ENDORSEMENT (59 MDW/SGVU Use Only)</b>			
TO: Clinical Research Division 59 MDW/CRD Contact 292-7141 for email instructions.	22. DATE RECEIVED December 19, 2016	23. ASSIGNED PROCESSING REQUEST FILE NUMBER 17014	
24. DATE REVIEWED December 19, 2016		25. DATE FORWARDED TO 502 ISG/JAC	
26. AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGES: <input checked="" type="checkbox"/> NO <input type="checkbox"/> YES If yes, give date. _____ <input type="checkbox"/> N/A			
27. COMMENTS <input checked="" type="checkbox"/> APPROVED <input type="checkbox"/> DISAPPROVED Draft version of IRB exempt determined study with appropriate disclosures. Approved with pending final revisions for publication			
28. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER Kevin R. Kupferer/GS13/Human Research Subject Protection Expert		29. REVIEWER SIGNATURE KUPFERER KEVIN R. 1086667270 <small>Digital signed by KUPFERER KEVIN R. 1086667270            Date: 2016.12.19 15:55:45 -0500</small>	30. DATE December 19, 2016
<b>2nd ENDORSEMENT (502 ISG/JAC Use Only)</b>			
31. DATE RECEIVED		32. DATE FORWARDED TO 59 MDW/PA	
33. COMMENTS <input type="checkbox"/> APPROVED (In compliance with security and policy review directives.) <input type="checkbox"/> DISAPPROVED			
34. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER		35. REVIEWER SIGNATURE	36. DATE
<b>3rd ENDORSEMENT (59 MDW/PA Use Only)</b>			
37. DATE RECEIVED 19 DEC 2016		38. DATE FORWARDED TO 59 MDW/SGVU	
39. COMMENTS <input checked="" type="checkbox"/> APPROVED (In compliance with security and policy review directives.) <input type="checkbox"/> DISAPPROVED			
40. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER JERILYN QUINTANILLA, SSGT, 59 MDW/PA		41. REVIEWER SIGNATURE  <small>Digital signed by QUINTANILLA JERILYN THERESE 1580778832            Date: 2016.12.23 15:58:55 -0500</small>	42. DATE 23 DEC 2016
<b>4th ENDORSEMENT (59 MDW/SGVU Use Only)</b>			
43. DATE RECEIVED		44. SENIOR AUTHOR NOTIFIED BY PHONE OF APPROVAL OR DISAPPROVAL <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> COULD NOT BE REACHED <input type="checkbox"/> LEFT MESSAGE	
45. COMMENTS <input type="checkbox"/> APPROVED <input type="checkbox"/> DISAPPROVED			
46. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER		47. REVIEWER SIGNATURE	48. DATE

Name of Journal of Ocular Pharmacology and Therapeutics, <http://mc.manuscriptcentral.com/ocular>

**Dose uniformity of topical corticosteroids: A simulated trial  
fluorometholone acetate 0.1% (Flarex®) and loteprednol  
etabonate gel 0.5% (Lotemax®)**

Journal:	<i>Journal of Ocular Pharmacology and Therapeutics</i>
Manuscript ID	JOP-2016-0151.R3
Manuscript Type:	Original Article
Date Submitted by the Author:	16-Nov-2016
Complete List of Authors:	Stevens, Charlton; San Antonio Military Medical Center, Bennion, John; Wilford Hall Ambulatory Surgical Center, Ophthalmology Caldwell, Matthew ; Wilford Hall Ambulatory Surgical Center, Ophthalmology Townley, James ; Wilford Hall Ambulatory Surgical Center, Ophthalmology Douglas , Apsey; Wilford Hall Ambulatory Surgical Center, Ophthalmology Schwertner, Harvey ; Wilford Hall Ambulatory Surgical Center, Clinical Research
Research Area:	Drug Delivery
Keywords:	Anti-inflammatory, Clinical Pharmacology, Drug Formulation, Eye Drops
Manuscript Keywords (Search Terms):	Fluorometholone acetate, loteprednol etabonate, dose uniformity, ophthalmic formulation, simulated dosing

SCHOLARONE<sup>®</sup>  
Manuscripts

Disclaimer: The views expressed are that of the author(s)/presenter(s) and do not reflect the official views or policy of the Department of Defense or its Components.



Charlton E Stevens

Correspondence: John Bennion, MD  
2200 Bergquist Dr, San Antonio, TX 78236  
Tel: 210-292-6583; Fax: 210-292-6569

E-mail: [bennion.john@gmail.com](mailto:bennion.john@gmail.com)

Word count: 1,483

**Dose uniformity of topical corticosteroids: A simulated trial  
fluorometholone acetate 0.1% and loteprednol etabonate gel 0.5%**

Charlton E Stevens<sup>1</sup>John L Bennion<sup>\*2</sup>Matthew C Caldwell<sup>2</sup>James R Townley<sup>2</sup>Douglas A Apsey<sup>2</sup>Harvey A Schwertner<sup>3</sup>

<sup>1</sup>Intern, San Antonio Military Medical Center, San Antonio, TX 78219

<sup>2</sup>Department of Ophthalmology, Wilford Hall Ambulatory Surgical Center  
JBSA Lackland, TX 78236

<sup>3</sup>Clinical Research, Wilford Hall Ambulatory Surgical Center JBSA Lackland, TX 78236

Disclosure: The views expressed are those of the author(s)/presenters(s) and do not reflect the official views of the Department of Defense. There are no financial or proprietary interests of any of the authors.

Funding: provided by the United States Air Force.

Keywords: Fluorometholone acetate, loteprednol etabonate, Flarex®, Lotemax®, dose uniformity, ophthalmic formulation, simulated dosing

Charlton E Stevens

## Abstract

**Purpose:** The purpose of the study was to determine the concentrations of Flarex® and Lotemax® when shaken and not shaken. Many patients fail to shake or inappropriately shake suspensions of corticosteroids prior to instillation as directed. This study was designed to help determine what concentration of corticosteroid these patients are receiving. In addition, independent confirmation of loteprednol etabonate ophthalmic gel dose uniformity was determined and compared as a possible alternative.

**Methods:** Drug concentrations of shaken versus unshaken Flarex® and Lotemax® were determined over a 20 day simulated tapered course in our institutional laboratory. Collected samples were analyzed by reversed phase high performance liquid chromatography (HPLC) with photodiode array detection at 240 nm.

**Results:** Flarex® had a mean concentration of 93.7% of the declared concentration when shaken and 7.25% when not shaken. The difference between these groups was statistically significant ( $p=0.0001$ ). Lotemax® had a mean concentration of 96.74% of the declared concentration when shaken and a mean concentration of 98.97% when not shaken. The difference between these groups was not statistically significant ( $p=0.194$ ).

**Conclusions:** Flarex® maintains dose uniformity when shaken. When not shaken it has poor dose uniformity. Lotemax® was consistent whether shaken or not in our study and can be considered to eliminate the variability of poor patient compliance with shaking. The manufactures of both drugs recommend shaking prior to application. Formulations of ocular corticosteroids that do not require shaking such as Lotemax® should be considered to eliminate the variability of poor patient compliance with shaking.

## Introduction

Topical ophthalmic corticosteroids are essential in the management of inflammation in the eye including following ocular surgery.<sup>1</sup> They are available in different forms including emulsions, ointments, solutions, gels, and suspensions. The choice of corticosteroid depends on the patient's disease condition, adverse side effect profile, strength of corticosteroid required, target tissue, and patient compliance.<sup>2</sup> Suspension formulations are commonly used, though a limitation is the need for adequate shaking immediately prior so as to ensure homogeneity.<sup>3</sup> Otherwise an unknown dose would be delivered. Apt et al showed that as many as two thirds of patients do not shake the ophthalmic corticosteroids suspensions before administering a dose.<sup>4</sup>

Fluorometholone acetate (Flarex®) (Alcon Laboratories Inc; Fort Worth, TX) is a commonly used corticosteroid suspension that requires **vigorous** shaking prior to application.<sup>5</sup> Loteprednol etabonate ophthalmic gel 0.5% (Lotemax®) (Bausch and Lomb Inc; Tampa, FL) is a newer formulation with comparable efficacy to other corticosteroids and the manufacturer recommends **to invert closed bottle and shake once to fill tip before instilling drops**. Lotemax has equal dose uniformity whether shaken or not.<sup>6</sup> Both medications are used in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.<sup>5,7</sup> They are frequently used following refractive surgery in managing inflammation and modulating wound healing.<sup>1,8</sup>

Loteprednol etabonate (LE) ophthalmic gel 0.5% is a formulation of LE approved by the US Food and Drug Administration (FDA) in 2012. This drug is unique compared



Charlton E Stevens

1  
2  
3 to many other ocular corticosteroids in its ability to change from a gel to a liquid upon  
4  
5 increased shear stress, thus converting to a liquid form when squeezed from the bottle.<sup>9</sup>  
6  
7 After application to the corneal surface it remains liquid owing to its polycarbophil  
8  
9 polymer that promotes its more viscous structure on the ocular surface.<sup>9</sup> Lotemax® gel  
10  
11 has been shown to have dose consistency after dispersion analysis demonstrated no  
12  
13 sedimentation of drug particles.<sup>10</sup>  
14  
15

16  
17 Due to its gel formulation, Lotemax® remains homogenous and should not  
18  
19 require shaking to achieve dose uniformity. This property eliminates dependence on  
20  
21 patient compliance to shake before dosing. One previous study demonstrated that LE  
22  
23 gel (Lotemax®) has superior dose uniformity compared to prednisolone acetate  
24  
25 suspension when not shaken.<sup>10</sup>  
26  
27

28  
29 The goal of this study was to determine the difference in the concentrations that  
30  
31 patients might actually be receiving when corticosteroid suspension Flarex® is  
32  
33 adequately shaken versus not shaken. We also sought to independently confirm  
34  
35 Lotemax® gel dose uniformity.  
36  
37  
38  
39  
40

## 41 Materials

### 42 Drugs and chemicals

43  
44 Fluorometholone acetate ophthalmic suspension, 0.1% (Flarex®) was obtained  
45  
46 from Alcon Laboratories, Ft. Worth, TX. Loteprednol etabonate ophthalmic gel, 0.5%  
47  
48 (Lotemax®) was obtained from Bausch and Lomb, Inc., Tampa, FL. Fluorometholone  
49  
50 acetate USP Reference Standard (200.0 mg) was obtained from US Pharmacopeia,  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Rockville, MD. Methanol, (HPLC grade), was obtained from Sigma-Aldrich, ST. Louis, MO.

### HPLC analysis of fluorometholone acetate and loteprednol etabonate

HPLC analysis of fluorometholone acetate and loteprednol etabonate was performed on a Waters Acquity Ultra Performance Liquid Chromatographic System equipped with an Acquity Binary Solvent and Sample Manager, Acquity Photodiode Array Detector (PDA), Empower 3 software, and a Phenomenex Luna C18 reversed phase column (2.0 x 150 mm, 5.0  $\mu$ , Cat.No. 475946-1). The HPLC mobile phase was methanol (100 %), the chromatographic flow rate was 0.25 mL/min., and the quantitation of both drugs was performed at 240 nm.

### Methods

This is an institutional experimental laboratory study without human subjects.

Six commercial bottles of Lotemax® gel (0.5% 5mL container) and six commercial bottles of Flarex® (0.1% 5mL container) were purchased and stored at room temperature. The bottles were individually labeled and then shaken per manufacturer instructions 2 days prior to day 1 of the experiment in order to establish a consistent baseline for when the bottles were last shaken or handled.

Three Flarex® bottles were vigorously shaken for 5 seconds immediately before dispensing, and three designated bottles were unshaken. The unshaken samples were collected by tipping the bottle 180 degrees, dispensing the drops, and then returning the bottle to its original upright position. Two drops were dispensed for each sample. Days 1-5: drops were dispensed 4 times daily but only collected for analysis on the first and



Charlton E Stevens

last times. Days 6-10: drops were dispensed 3 times daily but only collected for analysis on the first and last times. Days 11-15: drops were dispensed 2 times daily, both of which were collected for analysis. Days 16-20: drops were dispensed 1 time daily and collected for analysis. Figure 1 illustrates pictures taken of the solution at different points in time.

Similarly, three Lotemax® bottles were shaken and three others were unshaken. Collecting method and course for Lotemax® shaken and unshaken bottles were exactly the same as described for Flarex®. Figure 2 illustrates pictures taken of the solution at different points in time.

Three bottles for each subgroup, of shaken vs unshaken, were tracked independently to account for variability. A 20 day tapered course was chosen to determine the dosing concentrations through the span of a full bottle with a volume of 5mL (which contains approximately 100 drops). The two arms of the study required a total of 420 samples (35 samples from 12 separate bottles) to be analyzed.

## Results

The drug concentrations were determined and reported as percent of the declared bottle concentration. The declared bottle concentrations were 0.1% and 0.5% for Flarex® and Lotemax® respectively.

Figure 3 shows the drug concentrations of Flarex® comparing shaken to unshaken samples. The difference between Flarex® shaken and unshaken for the declared concentration was found to be statistically significant ( $p=0.0001$ ) using repeated measures analysis of variance (RM ANOVA). The average concentration for

the Flarex® NOT shaken was 7.25% of the declared concentration (with a standard deviation of 2.44%) whereas shaken was 93.79% of the declared concentration (with a standard deviation of 2.95%). Figure 1 demonstrates visual appearance of the settling of the solution.

Figure 4 shows the drug concentrations of Lotemax® gel comparing shaken to unshaken samples. The difference between Lotemax® gel shaken and unshaken for the declared concentration was not found to be statistically significant ( $p=0.194$ ) using repeated measures analysis of variance (RM ANOVA). The average concentration for the Lotemax® gel not shaken was at 98.97% of the declared concentration (with a standard deviation of 1.39%) whereas shaken was 96.74% of the declared concentration (with a standard deviation of 1.73%). Figure 2 demonstrates visually the lack of the settling of the solution.

The unshaken Lotemax® gel was on average within 1.10% (SD 1.39%) of the declared concentration whereas the unshaken Flarex® was on average within 92.72% (SD of 2.44%) of the declared concentration.

## Discussion

Often poor patient compliance leads to improper dosing of topical corticosteroid suspensions such as Flarex® despite clear instructions by manufacturer and prescriber. According to this study, if not shaken, patients would receive only 7.25% of the intended concentration. This much lower dose could have a clinically significant impact. However, when shaken appropriately, a satisfactory concentration is consistently obtained. This reiterates the importance of properly instructing patients to shake the suspension per



Charlton E Stevens

1  
2  
3 manufacturer instructions prior to instillation as well as the need for good patient  
4  
5 compliance.  
6

7 Lotemax® gel 0.5% on the other hand eliminates the reliance on shaking. The  
8  
9 ability of the drug to maintain a gel formulation until sheer stress is applied and then  
10  
11 remain liquid upon application results in a homogeneous solution that does not require  
12  
13 mixing prior to application. This uniform dosing, whether shaken or not, was confirmed  
14  
15 in this study. Figure 1 illustrates the settling effect of Flarex® with time. Figure 2  
16  
17 illustrates the preservation of homogeneity of Lotemax® gel with time despite not being  
18  
19 shaken.  
20  
21  
22  
23

24 Results for this study were consistent with a study by Marlow and Davio  
25  
26 demonstrating that Lotemax® gel maintains a homogeneous solution. Marlow et al  
27  
28 demonstrated that the average percent declared concentration of unshaken Lotemax®  
29  
30 gel was 102%.<sup>10</sup> This was compared with unshaken prednisolone acetate 1% (brand  
31  
32 name and generic), which demonstrated highly variable drop concentrations and mean  
33  
34 concentrations of 18.5% and 22.0% respectively. Our study also showed low mean  
35  
36 concentrations when not shaken but did not show the same high variability. The results  
37  
38 for their shaken medications were consistent with our study. Their study demonstrated  
39  
40 that after being shaken for 5 seconds Lotemax® gel had an average declared  
41  
42 concentration of 102%. The prednisolone acetate 1% formulations both had average  
43  
44 declared concentrations of 103% when shaken.  
45  
46  
47  
48  
49

50 Another study done by Stringer and Bryant compared dose uniformity of  
51  
52 difluprednate ophthalmic emulsion (Durezol®) with prednisolone acetate (brand name  
53  
54 and generic).<sup>11</sup> Similarly, prednisolone acetate 1% brand name and generic showed  
55  
56  
57  
58  
59  
60

high variability when not shaken whereas difluprednate had consistent dose uniformity whether shaken or not.

Clinical correlation of poor dose uniformity has not yet been determined and is an area of possible future investigation. Meanwhile, it is reasonable to assume that having consistent uniform dosing should lead to more predictable outcomes in management. If patients follow manufacturer instructions for either product, no dose non-uniformity is expected. Thus the importance of properly shaking corticosteroid suspensions such as fluorometholone acetate should be stressed, or the need for shaking may be avoided altogether by using other formulations such as loteprednol etabonate gel.

Correspondence: John Bennion, MD

2200 Bergquist Dr, San Antonio, TX 78236

Tel: 210-292-6583; Fax: 210-292-6569

E-mail: bennion.john@gmail.com

#### Acknowledgements

Author Disclosure statement: No competing financial interests exist in any author

There are no conflicts of interest.

Funding/Support: Funding was provided by the United States Air Force

Financial Disclosures: No financial disclosures

Other acknowledgements: views expressed are those of the author(s)/presenters(s) and do not reflect the official views of the Department of Defense.



## References

- 1 Mcghee CN, Dean S, Danesh-meyer H. Locally administered ocular corticosteroids: benefits and risks. *Drug Saf.* 2002;25(1):33-55.
- 2 University of Massachusetts Medical School. Therapeutic Class Overview Ophthalmic Steroids.  
<https://www.medicaid.nv.gov/Downloads/provider/Ophthalmic%20Steroids%202013-0206.pdf>. January 10, 2013. Accessed December 7, 2015.
- 3 Diestelhorst M, Kwon KA, Suverkrup R. Dose Uniformity of ophthalmic suspension. *J Cataract Refract Surg.* 1998;24(5):672-677.
- 4 Apt L, Henrick A, Silverman LM. Patient compliance with use of topical ophthalmic corticosteroid suspensions. *Am J Ophthalmol.* 1979;87(2): 210–214.
- 5 Flarex® [package insert]. Fort Worth, TX: Alcon Laboratories Inc; 2006.
- 6 Amon M, Busin M. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use. *Int Ophthalmol.* 2012;32(5):507-17.
- 7 Lotemax® suspension [package insert]. Tampa, FL: Bausch and Lomb Inc; 2006.
- 8 Roberts CW, Nelson PL. Comparative analysis of prednisolone acetate suspensions. *J Ocul Pharmacol Ther.* 2007;23(2):182–187.
- 9 Coffey MJ, Davio SR. Viscoelastic and sedimentation characterization of loteprednol etabonate ophthalmic gel (0.5%). Poster presented at: The Association for Research in Vision and Ophthalmology (ARVO); May 2012; Fort Lauderdale, FL.

10 Marlow ZT, Davio SR. Dose Uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%). *Clin Ophthalmol*. 2014;8:23-29.

11 Stringer W, Bryant R. Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%. *Clin Ophthalmol*. 2010; 5(4): 1119-1124.




## Figures

Figure 1: Settling affect of Flarex® with time. From left to right immediately following shaking, four hours after being shaken, eight hours after being shaken, twelve hours after being shaken. The picture is a collection of individual images.


Figure 2: Non-settling effect of Lotemax® gel with time. From left to right immediately following shaking, four hours after being shaken, eight hours after being shaken, twelve hours after being shaken. The picture is a collection of individual images.

Figure 3: Drug concentrations in drops of Flarex® comparing shaken immediately prior to simulated dosing to NOT shaken

Figure 4: Drug concentrations in drops of Lotemax® gel comparing shaken immediately prior to simulated dosing to NOT shaken




410x175mm (300 x 300 DPI)




409x166mm (300 x 300 DPI)





108x59mm (300 x 300 DPI)



108x60mm (300 x 300 DPI)

**Wilford Hall Ambulatory Surgical Center  
Institutional Review Board (IRB)**  
59th Clinical Research Division/SGVUS/(210) 292-7143  
2200 Bergquist Dr, Bldg 4430, Lackland AFB, TX 78236-5300  
Federal Wide Assurance #FWA00001750 and DoD Assurance #50007

26 Feb 14

**FINAL DETERMINATION**

**Determination Date:** 24 Feb 2014

**Project Lead:** Capt John Bennion/SGVT

**Reference Number:** FWH20140054N (IRBNet ID: 397493-1)

**Project Title:** Dose uniformity of topical corticosteroid ophthalmic medications: flourometholone acetate 0.1% suspension, loteprednol etabonate 0.5% suspension, and loteprednol etabonate 0.5% gel

Your project was determined on 24 Feb 2014 to be considered **not human research** as defined by DoD regulations at **32 CFR 219 and FDA regulations at 21 CFR 56**. You are not required to obtain IRB approval for this activity. The proposed project does not include non-routine intervention or interaction with a living individual for the primary purpose of obtaining data regarding the effect of the intervention or interaction, nor do the researchers obtain private, identifiable information about living individuals.

If the goals and/or activities of the project change during the course of the project, or if new activities are proposed that would constitute human subjects research, re-contact the Protocol Office so that a regulatory expert may determine whether or not the revised plan involves human subject research activities.

Additional items reviewed and approved by the WHASC/IRB include:

Intramural Funding Support Document  
Letter of Support- CRD Lab

**DOMINGUEZ.MA  
RIA.E.1231107742**

Digitally signed by  
DOMINGUEZ.MARIA.E.1231107742  
DN: c=US, o=U.S. Government, ou=DoD,  
ou=PKI, ou=USAF,  
cn=DOMINGUEZ.MARIA.E.1231107742  
Date: 2014.02.26 14:31:58 -06'00'

Maria Dominguez, CIV, DAF  
Clinical Research Protocol Assistant